Enhancement of Gemcitabine sensitivity in pancreatic adenocarcinoma by novel exosome-mediated delivery of the Survivin-T34A mutant

BACKGROUND: Current therapeutic options for advanced pancreatic cancer have been largely disappointing with modest results at best, and though adjuvant therapy remains controversial, most remain in agreement that Gemcitabine should stand as part of any combination study. The inhibitor of apoptosis (...

Descripción completa

Detalles Bibliográficos
Autores principales: Aspe, Jonathan R., Diaz Osterman, Carlos J., Jutzy, Jessica M.S., Deshields, Simone, Whang, Sonia, Wall, Nathan R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Co-Action Publishing 2014
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929070/
https://www.ncbi.nlm.nih.gov/pubmed/24624263
http://dx.doi.org/10.3402/jev.v3.23244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929070/
https://www.ncbi.nlm.nih.gov/pubmed/24624263
http://dx.doi.org/10.3402/jev.v3.23244

Ejemplares similares